PAGINA 0

CREATA PENTRU A PUTEA SEMNA ELECTRONIC DOCUMENTUL

EnChEVAR Elevating ChEVAR therapy

Check out latest clinical data



Discover EnChEVAR

Explore latest clinical

Watch experts testimonials

Our Impact

View stent graft sizing guidelines

EnChEVAR with Endurant™ II/IIs stent graft system + Radiant[™] balloon-expandable covered stent

Our Company

Proven device combination for ChEVAR.

EnChEVAR with EndurantTM II/IIs system + RadiantTM covered stent demonstrates durable clinical outcomes (mean f/u 24.6 ± 17.4 months)1:

 1.6% new late onset type la endoleak benefits



Proven, safe, and effective way to lengthen aortic sealing zones

Learn how EnChEVAR with EndurantTM II/IIs system + RadiantTM stent provides durable outcomes in challenging EnChEVAR deployment

hostile sealing zones.

Step-by-step deployment of the EndurantTM II/IIs and Radiant™ stent grafts for ChEVAR.II

Clinical outcomes


ENCHANT Trial³ 1-year data release

EnChEVAR (Endurant II/IIs stent graft system + Radiant[†] balloon-expandable covered stent) analysis (n = 62)³

ENCHANT is a multicentre, prospective, single-arm, post-market study to assess the clinical outcomes, safety, and performance of the Endurant II/IIs system used with balloon expandable covered stents for treatment of juxtarenal aortic aneurysms with a short infrarenal neck in a real-world setting.

Key outcomes of the one year Kaplan-Meier analyses.

- 29 centres in EU and Russia
- Freedom from all cause mortality: 87.0 ± 4.3%
- Freedom from aneurysm rupture: 100% Freedom from conversion: 100%
- Freedom from all secondary procedures: 88.0 ± 4.3%
- Freedom from secondary procedures to treat type la endoleak: 100%



- One year sac status by Core Lab (n = 41)‡
- 2.4% sac increase
- 68.3% sac stable • 29.3% sac decrease





PROTAGORAS study

The PROTAGORAS study¹ evaluated the performance of the EndurantTM II/IIs stent graft for patients with pararenal pathologic processes that were treated by the chemistry/snorkel endovascular technique.

Standardised use of the Endurant™ II/IIs stent graft system and Radiant™ covered stent for ChEVAR demonstrated:

 $N = 128 \text{ patients}^1$

24.6 months mean radiologic follow-up (range, 0-61 months)

- 100% technical success New late onset of type la endoleaks: 1.6%
- Primary patency of chimney grafts: 95.7% AAA sac diameter regression/stability: 90.6%
- Freedom from chimney graft-related reinterventions: 93.1%

RadiantTM covered stent shows significantly better performance in ChEVAR compared to other grafts, with 94.6% patency at midterm compared to 84.1% patency with other covered stents.2



Expand All

View brochure for full details.

Download brochure [3]

Experts testimonials

Our experts tell it best. Watch their testimonials



Our experts tell it best. Clinician experiences on EnChEVAR

Prof. Reijnen and Prof. Donas share their clinical experience about EnChEVAR technique with Endurant™ II/IIs system

Stent graft sizing

and RadiantTM covered stent.

Use this tool to see full ordering information and plan case specifics such as sizing and placement.

→ Endurant™ II/IIs stent graft sizing guidelines → Radiant™ stent graft sizing guidelines → RadiantTM stent graft size configurations

Sizing sheet [2]

Preparing for the case Recommended ancillary equipment§:

Soft wire for easy access to renal arteries

 0.035" soft Terumo GLIDEWIRE™* hydrophilic-coated guidewire

and flexibility; atraumatic short tip Cook Rosen™* wire guide

Renal wire balanced between stiffness

7 F sheath, 90 cm length with atraumatic tip for renal entry

 Medtronic TourGuide™ steerable sheath 7 F, 90 cm Cook Flexor™* Shuttle™* guiding sheath, Terumo Destination™* guiding sheath

Shorter 16 F sheath or larger may be used for access during a two-chimney case.

Catheter – 5 F, minimum length of 110 cm to 125 cm

Must be able to pass through and extend beyond 90 cm sheath; variety of angles to support renal cannulation;

vertebral multipurpose.

- Balloons Medtronic Reliant™ stent graft balloon catheter to
- II/IIs stent graft system with the aortic wall and the renal Medtronic Admiral Xtreme™ PTA balloon catheter OTW 0.035" assist in access to renal (4 mm x 40 mm)

achieve good conformability of the Medtronic Endurant.

Inflation devices

- 20 cc syringe
- 20 cc inflation device equipped with manometer

Related pages

- Endurant™ II/IIs Stent Graft System Radiant™ Balloon Expandable Covered Stent
- Clinical outcomes

Aortic catalog Choose from a complete portfolio of

market leading aortic vascular therapies to treat aneurysm disease.

Contact us

Request more

information

View catalog □

* Third-party brands are trademarks of their respective owners.

† Patients in this dataset were treated with Advanta V12, which was re-labelled as Radiant and received CE mark approval in September 2022 for use in ChEVAR.

* Denominator is the number of subjects with Core Lab-reported maximum aneurysm diameter at both one month post-implant and one-year follow-

 Other covered stents include: GORE Viabahn®*, Bentley BeGraft™*, BD LifeStream***. # All indications related to the Endurant™ II/IIs and Radiant™ stent grafts are not approved globally. Please check your local regulatory approval

status. Refer to the complete Instructions for Use manual of the EndurantTM II/IIs and RadiantTM stent grafts for the indications approved in your geography.

References

* Donas KP, Torsello GB, Piccoli G, et al. The PROTAGORAS study to evaluate the performance of the Endurant stent graft for patients with pararenal pathologic processes treated by the chimney/snorkel endovascular technique. J Vasc Surg. January 2016;63(1):1-7.

⁷ Pitaulias GA, Torsello G, Austermann M, et al. Outcomes of elective use of the chimney endovascular technique in pararenal sortic pathologic processes. J Vasc Surg. February 2021;73(2):433-442.

³ Prof. Giovanni Torsello. "ENCHANT Trial interim analysis: Endurant ChEVAR technique for juxtarenal aneursyms." Presented at LINC, June 8, 2023;

Brief statement: See the device manual for detailed information regarding the instructions for use, the implant procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at medtronic.eu. For applicable products, consult instructions for use on www.medtronic.com/manuals. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.

Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.

Overview Overview Products

Therapies & Procedures Integrated Health Solutions

HEALTHCARE PROFESSIONALS

PATIENTS

OUR COMPANY

Who We Are Key Facts Leadership History Mission Locations

Governance [1

Careers

Our Impact Healthcare access Inclusion, Diversity & Equity Protecting our planet **ESG Report**

UC202217626cEE Last Updated September 2023 © 2023 Medtronic

OUR IMPACT

Privacy Statement | Terms of Use | Contact